##plugins.themes.academic_pro.article.sidebar##
Main Article Content
Abstract
Background: Osteosarcoma is the most common primary bone malignancy. Although the primary tumor has been resected, the patient remains at high risk of metastases. The incidence and clinicopathological characteristics of osteosarcoma need to be studied.
Aim: To obtain epidemiological data that can help in diagnosis and management of osteosarcoma.
Methods: This research was conducted in a retrospective descriptive manner. The data obtained from medical records at the Anatomical Pathology Laboratory, RSU Dr. Saiful Anwar Malang in 2018-2020 which met the inclusion criteria and exclusion criteria. The variables studied included gender, age, location, subtype, grade, Huvos assessment.
Results: There were 68 cases of osteosarcoma that met the criterias. Most of the patients were male (52.94%). The age of the patients was spread from 8 years to 79 years. With average age was 24.56 years, the median age was 16 years, and the most in the age range of 11-25 years. The most common location was the lower extremity (82.35%). The most subtype was osteosarcoma NOS (94.12%). The most cases were high grade (94.12%). From all of cases, 3 cases were huvos graded, 1 case were grade 1, and 2 cases were grade 2.
Conclusion: Most Osteosarcoma patient are men, most often in the age range of 11-25 years. The most common location is in the lower extremities, the most subtype is osteosarcoma NOS, the most grade is High grade. Most of the cases were not carried out by huvos grading.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
2. Prater S, Mckeon B. Cancer , Osteosarcoma. Published online 2020:1-16. https://www.ncbi.nlm.nih.gov/books/NBK549868/
3. IARC. WHO Classification of Soft Tissue and Bone Tumours. 5TH ed.; 2020. doi:10.1017/CBO9780511545375.031
4. Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer. 2018;65(9):1-9. doi:10.1002/pbc.27227
5. Zhu T, Ye Z. Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma : a meta-analysis. Published online 2016:1477-1487.
6. Sui Y, Han Y, Zhao X, Li D, Li G. Long non-coding RNA GClnc1 promotes tumorigenesis in osteosarcoma by inhibiting p53 signaling. Biochem Biophys Res Commun. 2018;507(1-4):36-42. doi:10.1016/j.bbrc.2018.10.135
7. Mahyudin F, Edward M, Basuki MH, Bari YA, Suwandani Y. Osteosarcoma Has Not Become Attention To Society Profile of Osteosarcoma Patients At Dr. Soetomo General Hospital Surabaya “a Retrospective Study.” J Orthop Traumatol Surabaya. 2019;7(1):20.
doi:10.20473/joints.v7i1.2018.20-30
8. Vinay Kumar abdul KA. Robbins Basic Pathology, 10th Edition. 10th ed. elsevier; 2018.
9. Mintaroem K, Prabawati D, Mudjiwiyono, Khasana R. Patologi Umum Dan Pemeriksaan Patologi. 2nd ed. (eviana n rachmad s, ed.).; 2016.
10. Kim SH, Shin KH, Moon SH, Kong Y, Suh JS, Yang WI. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma. J Surg Oncol. 2017;115(6): 752-759. doi:10.1002/jso.24571
11. Orell SR. Orell & Sterrett ’ s Fine Needle Aspiration Cytology , Fifth Edition. Published online 2012.
12. Dabbs DJ. Diagnostic Immunohistochemistry Theranostic and Genomic Applications. Published online 2014.
13. Valery PC, Laversanne M, Bray F. Bone cancer incidence by morphological subtype: a global assessment. Cancer Causes Control. 2015;26(8):1127-1139. doi:10.1007/s10552-015-0607-3
14. Yoshida A, Ushiku T, Motoi T, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23(9):1279-1288. doi:10.1038/modpathol.2010.124
15. Komite Penanggulanan Kanker Nasional. Panduan Penatalaksanaan Osteosarkoma. Kom Penanggulangan Kanker Nas. Published online 2015:1-40.
http://kanker.kemkes.go.id/guidelines/PPKOsteosarkoma.pdf